LON:GNS - Genus Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started GBX 2,140 -10.00 (-0.47 %) (As of 11/18/2018 02:02 PM ET)Previous CloseGBX 2,140Today's RangeGBX 2,106 - GBX 2,16452-Week RangeGBX 1,652 - GBX 2,597Volume59,076 shsAverage Volume78,154 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartDividendInsider TradesHeadlines Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Genus plc, together with its subsidiaries, engages in the application of quantitative genetics and biotechnology for animal breeding in the porcine and bovine sectors. It operates through three segments: Genus PIC, Genus ABS, and Research and Development. The company sells sows, boars, and semen under the PIC name to breed pigs with various characteristics for pork production. It also sells bull semen and embryos that are delivered through artificial insemination to breed diary and beef cattle with various characteristics for milk and beef production under the ABS name, as well as provides various in vitro fertilization services under the IVB name. The company serves pork, beef, and dairy farmers in North America, Latin America, rest of Europe, the Middle East, Africa, and Asia. Genus plc was incorporated in 1994 and is headquartered in Basingstoke, the United Kingdom. Receive GNS News and Ratings via Email Sign-up to receive the latest news and ratings for GNS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange LON Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolLON:GNS Previous Symbol CUSIPN/A Webwww.genusplc.com Phone+44-1256-347100 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous EmployeesN/A Outstanding SharesN/AMarket Cap£0.00 OptionableNot Optionable Genus (LON:GNS) Frequently Asked Questions What is Genus' stock symbol? Genus trades on the London Stock Exchange (LON) under the ticker symbol "GNS." How often does Genus pay dividends? What is the dividend yield for Genus? Genus announced a dividend on Thursday, September 6th. Investors of record on Thursday, November 15th will be given a dividend of GBX 17.90 per share on Friday, November 30th. This represents a yield of 0.7%. The ex-dividend date is Thursday, November 15th. This is a positive change from Genus's previous dividend of $8.10. The official announcement can be viewed at this link. View Genus' Dividend History. What price target have analysts set for GNS? 4 brokerages have issued 1-year target prices for Genus' shares. Their forecasts range from GBX 1,800 to GBX 2,600. On average, they anticipate Genus' stock price to reach GBX 2,335 in the next year. This suggests a possible upside of 9.1% from the stock's current price. View Analyst Price Targets for Genus. What is the consensus analysts' recommendation for Genus? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genus in the last year. There are currently 4 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Genus. Has Genus been receiving favorable news coverage? Media headlines about GNS stock have been trending somewhat positive recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Genus earned a daily sentiment score of 1.8 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the near future. Who are some of Genus' key competitors? Some companies that are related to Genus include 22nd Century Group (XXII), 4d Pharma (DDDD), Abattis Bioceuticals (ATTBF), Abcam (ABC), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Acasti Pharma (ACST), Acrux (ACR), Actinium Pharmaceuticals (ATNM), Almirall (LBTSF), Altimmune (ALT), Ampio Pharmaceuticals (AMPE), Ampliphi Biosciences (APHB) and Antibe Therapeutics (ATE). Who are Genus' key executives? Genus' management team includes the folowing people: Mr. Karim Bitar, Chief Exec. Officer and Exec. Director (Age 53)Mr. Stephen Wilson, Group Fin. Director & Exec. Director (Age 58)Dr. Jonathan Lightner Ph.D., Chief of R&D and Scientific OfficerMr. Dan Hartley, Group Gen. Counsel & Company Sec.Ms. Angelle R. Rosata SPHR, Group HR Director How do I buy shares of Genus? Shares of GNS and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Genus' stock price today? One share of GNS stock can currently be purchased for approximately GBX 2,140. What is Genus' official website? The official website for Genus is http://www.genusplc.com/. How can I contact Genus? Genus' mailing address is Matrix House, Basing View, BASINGSTOKE, RG21 4DZ, United Kingdom. The company can be reached via phone at +44-1256-347100. MarketBeat Community Rating for Genus (LON GNS)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 261 (Vote Outperform)Underperform Votes: 239 (Vote Underperform)Total Votes: 500MarketBeat's community ratings are surveys of what our community members think about Genus and other stocks. Vote "Outperform" if you believe GNS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/18/2018 by MarketBeat.com StaffFeatured Article: Are all No-Load Funds Equal?